Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06047210 · ClinicalTrials.gov registry record
Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis
A clinical trial, sponsored by Swedish Orphan Biovitrum.
- Completed
- Registry status
- 14
- Enrollment target
NCT06047210: Completed study, sponsored by Swedish Orphan Biovitrum.
NCT06047210 is a clinical trial that has completed, run by Swedish Orphan Biovitrum. The registered enrollment target is 14 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06047210 has completed, sponsored by Swedish Orphan Biovitrum.
- COMPLETED
- Registry status
- 14 participants
- Enrollment target
Study Summary
This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.
Primary Outcome
Serum samples was collected at various times after HLH diagnosis to determine the concentration of CXCL10.
Interventions
- OTHER Blood Draws Data Collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2016-12-14 |
| Est. Completion | 2019-10-30 |
What the finished NCT06047210 record still lists
NCT06047210 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 14 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Blood Draws Data Collection is the first listed.
NCT06047210 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06047210 about?
NCT06047210 is a clinical study titled "Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis". This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.
What is the current status of trial NCT06047210?
This trial is currently completed. The enrollment target is 14 participants. The study started on 2016-12-14. Estimated completion is 2019-10-30.
What interventions are being tested in trial NCT06047210?
The interventions under investigation include: Blood Draws Data Collection (OTHER).
Who is sponsoring clinical trial NCT06047210?
This trial is sponsored by Swedish Orphan Biovitrum, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy